242 related articles for article (PubMed ID: 33650210)
21. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
22. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
23. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration.
Lipner SR; Wang Y
J Am Acad Dermatol; 2020 Nov; 83(5):1527-1529. PubMed ID: 32652194
[No Abstract] [Full Text] [Related]
25. Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events.
Joung KI; Kim KH; Hsieh CY; Shin JY
Pharmacogenomics; 2020 Nov; 21(16):1157-1168. PubMed ID: 33118441
[No Abstract] [Full Text] [Related]
26. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
27. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
Sessa M; Andersen M
BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
[TBL] [Abstract][Full Text] [Related]
28. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
29. Safety Profile of Paxlovid in the Treatment of COVID-19.
Lv B; Gao X; Zeng G; Guo H; Li F
Curr Pharm Des; 2024; 30(9):666-675. PubMed ID: 38415446
[TBL] [Abstract][Full Text] [Related]
30. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
[TBL] [Abstract][Full Text] [Related]
31. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
32. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants.
Wong CK; Ho SS; Saini B; Hibbs DE; Fois RA
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):731-7. PubMed ID: 26017154
[TBL] [Abstract][Full Text] [Related]
33. Potential Signals of COVID-19 as an Effect Modifier of Adverse Drug Reactions.
Hauben M; Hung E; Chen Y
Clin Ther; 2024 Jan; 46(1):20-29. PubMed ID: 37919188
[TBL] [Abstract][Full Text] [Related]
34. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
35. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.
Dauner DG; Dauner KN
J Am Pharm Assoc (2003); 2021; 61(3):293-298. PubMed ID: 33546986
[TBL] [Abstract][Full Text] [Related]
36. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
37. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
[TBL] [Abstract][Full Text] [Related]
38. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
39. Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events.
Montes-Grajales D; Garcia-Serna R; Mestres J
Sci Rep; 2023 Nov; 13(1):18817. PubMed ID: 37914862
[TBL] [Abstract][Full Text] [Related]
40. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
